{"name":"FLUIDDA nv","slug":"fluidda-nv","ticker":"","exchange":"","domain":"","description":"FLUIDDA nv is a biotechnology company focused on the development of innovative treatments for respiratory diseases. The company has a pipeline of five drugs, primarily in Phase 3 clinical trials, including placebos and Seretide Evohaler.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Placebo of Reference product","genericName":"Placebo of Reference product","slug":"placebo-of-reference-product","indication":"Other","status":"phase_3"},{"name":"Placebo of Roflumilast","genericName":"Placebo of Roflumilast","slug":"placebo-of-roflumilast","indication":"Other","status":"marketed"},{"name":"Placebo of Test product","genericName":"Placebo of Test product","slug":"placebo-of-test-product","indication":"Other","status":"phase_3"}]},{"name":"Respiratory","slug":"respiratory","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Seretide Evohaler","genericName":"Seretide Evohaler","slug":"seretide-evohaler","indication":"Chronic obstructive pulmonary disease (COPD)","status":"phase_3"}]}],"pipeline":[{"name":"Placebo of Reference product","genericName":"Placebo of Reference product","slug":"placebo-of-reference-product","phase":"phase_3","mechanism":"A placebo formulation designed to match the physical and sensory characteristics of a reference product for blinded clinical trial comparison.","indications":[],"catalyst":""},{"name":"Placebo of Roflumilast","genericName":"Placebo of Roflumilast","slug":"placebo-of-roflumilast","phase":"marketed","mechanism":"This is a placebo formulation with no active pharmacological mechanism.","indications":[],"catalyst":""},{"name":"Placebo of Test product","genericName":"Placebo of Test product","slug":"placebo-of-test-product","phase":"phase_3","mechanism":"A placebo control product designed to match the appearance and administration route of FLUIDDA's test product for blinded clinical comparison.","indications":[],"catalyst":""},{"name":"Seretide Evohaler","genericName":"Seretide Evohaler","slug":"seretide-evohaler","phase":"phase_3","mechanism":"Seretide Evohaler is a combination of fluticasone and salmeterol, which work together to reduce inflammation and bronchospasm in the airways.","indications":["Chronic obstructive pulmonary disease (COPD)","Asthma"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":3,"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}